These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21924412)

  • 1. A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method.
    Zhong L; Ma CY; Zhang H; Yang LJ; Wan HL; Xie QQ; Li LL; Yang SY
    Comput Biol Med; 2011 Nov; 41(11):1006-13. PubMed ID: 21924412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting substrates of the human breast cancer resistance protein using a support vector machine method.
    Hazai E; Hazai I; Ragueneau-Majlessi I; Chung SP; Bikadi Z; Mao Q
    BMC Bioinformatics; 2013 Apr; 14():130. PubMed ID: 23586520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marine natural products as breast cancer resistance protein inhibitors.
    Cherigo L; Lopez D; Martinez-Luis S
    Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
    Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
    Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
    Garg P; Dhakne R; Belekar V
    Mol Divers; 2015 Feb; 19(1):163-72. PubMed ID: 25502234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
    Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
    Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of Breast Cancer Resistant Protein (BCRP) Inhibitors and Non-Inhibitors Using Machine Learning Approaches.
    Belekar V; Lingineni K; Garg P
    Comb Chem High Throughput Screen; 2015; 18(5):476-85. PubMed ID: 26004050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2).
    Ding YL; Shih YH; Tsai FY; Leong MK
    PLoS One; 2014; 9(3):e90689. PubMed ID: 24614353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening.
    Pan Y; Chothe PP; Swaan PW
    Mol Pharm; 2013 Apr; 10(4):1236-48. PubMed ID: 23418667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A; Zhang Y; Unadkat JD; Mao Q
    J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
    Juvale K; Pape VF; Wiese M
    Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
    Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
    J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
    Marighetti F; Steggemann K; Hanl M; Wiese M
    ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.